Author Title [ Type(Asc)] Year
Filters: Author is Yakoub-Agha, Ibrahim  [Clear All Filters]
Journal Article
Brissot E, Labopin M, Beckers MM, Socié G, Rambaldi A, Volin L, Finke J, Lenhoff S, Kröger N, Ossenkoppele GJ, et al. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. Haematologica. 2014.
Gagelmann N, Eikema D-J, Koster L, Caillot D, Pioltelli P, Lleonart JBargay, Reményi P, Blaise D, Schaap N, Trneny M, et al. Tandem autologous stem cell transplantation improves outcome in newly diagnosed multiple myeloma with extramedullary disease and high-risk cytogenetics: a study from the Chronic Malignancies Working Party of EBMT. Biol Blood Marrow Transplant. 2019.
Belkacemi Y, Labopin M, Giebel S, Gorin NClaude, Loganadane G, Miszczyk L, Michallet M, Socié G, Schaap NPm, Cornelissen JJ, et al. Single Dose Daily Fractionated Is Not Inferior To Twice A Day Fractionated Total Body Irradiation Prior To Allogeneic Stem Cell Transplantation For Acute Leukemia: A Useful Practice Simplification Resulting From The Sarasin Study. Int J Radiat Oncol Biol Phys. 2018.
Le Bourgeois A, Labopin M, Marçais A, de Latour RPeffault, Blaise D, Chantepie S, N'Guyen S, Maillard N, Forcade E, Yakoub-Agha I, et al. Sequential allogeneic hematopoietic stem cell transplantation for active refractory/relapsed myeloid malignancies: results of a reduced-intensity conditioning preceded by clofarabine and cytosine arabinoside, a retrospective study on behalf of the SFGM-TC. Ann Hematol. 2020.
Gauthier J, Damaj G, Yakoub-Agha I. [The role of pre-transplant debulking treatment in patients undergoing allogeneic stem cell transplantation for high-risk myelodysplastic syndrome]. Bull Cancer. 2015.
Garderet L, Sbianchi G, Iacobelli S, Blaise D, Byrne JL, Reményi P, Apperley JF, Touzeau C, Isaksson C, Browne P, et al. Prognostic impact of early-versus-late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: results from the CALM study by the CMWP of the EBMT. Eur J Haematol. 2021.
Fenwarth L, Thomas X, de Botton S, Duployez N, Bourhis J-H, Lesieur A, Fortin G, Meslin P-A, Yakoub-Agha I, Sujobert P, et al. A Personalized Approach to Guide Allogeneic Stem Cell Transplantation in Younger Adults with Acute Myeloid Leukemia. Blood. 2020.
Hayashi H, Volt F, Sanz J, Petersen E, Dhedin N, Hough R, Milpied N, Angelucci E, Yakoub-Agha I, Michallet M, et al. Myeloablative unrelated cord blood transplantation in adolescents and young adults with acute leukemia. Biol Blood Marrow Transplant. 2019.
Demaret J, Varlet P, Trauet J, Beauvais D, Grossemy A, Hégo F, Yakoub-Agha I, Labalette M. Monitoring CAR T-cells using flow cytometry. Cytometry B Clin Cytom. 2020.
Gilleece MH, Labopin M, Yakoub-Agha I, Volin L, Socié G, Ljungman P, Huynh A, Deconinck E, Wu D, Bourhis JHenri, et al. Measurable residual disease, conditioning regimen intensity and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: a registry analysis of 2292 patients by the Acute Leukemia Working Party Eu. Am J Hematol. 2018.
Bazarbachi A, Boumendil A, Finel H, Castagna L, Dominietto A, Blaise D, Diez-Martin JL, Tischer J, Gulbas Z, Wallet HL, et al. Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma - a LWP-EBMT study. Br J Haematol. 2019.
Robin M, Porcher R, Ruggeri A, Blaise D, Wolschke C, Koster L, Angelucci E, Stölzel F, Potter V, Yakoub-Agha I, et al. HLA mismatched donors in patients with myelodysplastic syndrome: an EBMT registry analysis. Biol Blood Marrow Transplant. 2018.
Cornillon J, Detrait M, Karam M, Le Bars L, Meziane Y, Pereira M, Richard-Leveille S, Marion S, Leroux S, Coiteux V, et al. [Harmonization of data coding in post-transplant follow-up - "GVHD, complications and additional treatments": Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer. 2018.
Fayard A, Daguenet E, Blaise D, Chevallier P, Labussière H, Berceanu A, Yakoub-Agha I, Socié G, Charbonnier A, Suarez F, et al. Evaluation of infectious complications after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide following reduced-intensity and myeloablative conditioning: a study on behalf of the Francophone Society of Stem Cell. Bone Marrow Transplant. 2019.
Chalandon Y, Passweg JR, Guglielmi C, Iacobelli S, Apperley J, Schaap NPM, Finke J, Robin M, Fedele R, Bron D, et al. Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT. Haematologica. 2014.
Shouval R, Fein JA, Labopin M, Cho C, Bazarbachi A, Baron F, Bug G, Ciceri F, Corbacioglu S, Galimard J-E, et al. Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry. Lancet Haematol. 2021;8(3):e205-e215.
Lee CJ, Labopin M, Beelen D, Finke J, Blaise D, Ganser A, Itälä-Remes M, Chevallier P, Labussière-Wallet H, Maertens J, et al. Comparative Outcomes of Myeloablative and Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Therapy-Related Acute Myeloid Leukemia with Prior Solid Tumor: a report from the ALWP of the EBMT. Am J Hematol. 2018.
de Latour RPeffault, Chevallier P, Blaise D, Alami S, Levy-Bachelot L, Allavoine T, Tadmouri A, Blomkvist J, Duhamel A, Srour M, et al. Clinical and Economic Impact of Treated CMV Infection in Adult CMV-seropositive Patients after Allogeneic Hematopoietic Cell Transplantation. J Med Virol. 2020.
Mohty M, Duléry R, Gauthier J, Malard F, Brissot E, Aljurf M, Bazarbachi A, Chabanon C, Kharfan-Dabaja MA, Savani BN, et al. CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview. Bone Marrow Transplant. 2020.
Bazarbachi A, Boumendil A, Finel H, Mohty M, Castagna L, Blaise D, Peggs KS, Afanasyev B, Díez-Martín JL, Corradini P, et al. Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party. Cancer. 2018.
Yakoub-Agha I, Deeg J. Are hypomethylating agents replacing induction-type chemotherapy prior to allogeneic stem cell transplantation in patients with myelodysplastic syndrome?. Biol Blood Marrow Transplant. 2014.
Radujkovic A, Dietrich S, Blok H-J, Nagler A, Ayuk F, Finke J, Tischer J, Mayer J, Koc Y, Sorà F, et al. Allogeneic stem cell transplantation for blast crisis chronic myeloid leukemia in the era of tyrosine kinase inhibitors - A retrospective study by the EBMT Chronic Malignancies Working Party. Biol Blood Marrow Transplant. 2019.
Nagler A, Rocha V, Labopin M, Unal A, Ben Othman T, Campos A, Volin L, Poire X, Aljurf M, Masszi T, et al. Allogeneic Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia in Remission: Comparison of Intravenous Busulfan Plus Cyclophosphamide (Cy) Versus Total-Body Irradiation Plus Cy As Conditioning Regimen--A Report From the Acute Leukemia Worki. J Clin Oncol. 2013.